Cellular models for beta cell function and diabetes gene therapy

AD Green, Srividya Vasu, Peter Flatt

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Diabetes is characterised by the destruction and/or relative dysfunction of insulin secreting beta-cells in the pancreatic islets of Langerhans. Consequently, considerable effort has been made to understand the physiological processes governing insulin production and secretion in these cells, and to elucidate the mechanisms involved in their deterioration in the pathogenesis of diabetes. To date, considerable research has exploited clonal beta-cell lines derived from rodent insulinomas. Such cell-lines have proven to be a great asset in diabetes research, in vitro drug testing, and studies of beta-cell physiology; and provide a sustainable, and in many cases, more practical alternative to the use of animals or primary tissue. However, selection of the most appropriate rodent beta cell-line is often challenging and no single cell line entirely recapitulates the properties of human beta-cells. The generation of stable human beta-cell lines would provide a much more suitable model for studies of human beta-cell physiology and pathology, and could potentially be used as a readily available source of implantable insulin-releasing tissue for cell-based therapies of diabetes. In this review, we discuss the history, development, functional characteristics and use of available clonal rodent beta-cell lines, as well as reflecting on recent advances in the generation of human derived beta-cell lines, their use in research studies, and their potential for cell-therapy of diabetes.
LanguageEnglish
Pagese13012-e13012
JournalActa Psychologica
Volume222
Issue number3
Early online date11 Dec 2017
DOIs
Publication statusE-pub ahead of print - 11 Dec 2017

Fingerprint

Genetic Therapy
Cell Line
Cell Physiological Phenomena
Rodentia
Cell- and Tissue-Based Therapy
Islets of Langerhans
Animal Use Alternatives
Research
Insulin
Physiological Phenomena
Insulinoma
Insulin-Secreting Cells
Cells
Gene Therapy
Diabetes
History
Pathology
Pharmaceutical Preparations

Keywords

  • Antidiabetic cell-therapy
  • Beta-cell replacement
  • Diabetes
  • Insulin
  • secreting cell-lines
  • Pancreatic beta-cell
  • Pseudoislets

Cite this

Green, AD ; Vasu, Srividya ; Flatt, Peter. / Cellular models for beta cell function and diabetes gene therapy. In: Acta Psychologica. 2017 ; Vol. 222, No. 3. pp. e13012-e13012.
@article{9b04a429dfb548398b49ca948f87475b,
title = "Cellular models for beta cell function and diabetes gene therapy",
abstract = "Diabetes is characterised by the destruction and/or relative dysfunction of insulin secreting beta-cells in the pancreatic islets of Langerhans. Consequently, considerable effort has been made to understand the physiological processes governing insulin production and secretion in these cells, and to elucidate the mechanisms involved in their deterioration in the pathogenesis of diabetes. To date, considerable research has exploited clonal beta-cell lines derived from rodent insulinomas. Such cell-lines have proven to be a great asset in diabetes research, in vitro drug testing, and studies of beta-cell physiology; and provide a sustainable, and in many cases, more practical alternative to the use of animals or primary tissue. However, selection of the most appropriate rodent beta cell-line is often challenging and no single cell line entirely recapitulates the properties of human beta-cells. The generation of stable human beta-cell lines would provide a much more suitable model for studies of human beta-cell physiology and pathology, and could potentially be used as a readily available source of implantable insulin-releasing tissue for cell-based therapies of diabetes. In this review, we discuss the history, development, functional characteristics and use of available clonal rodent beta-cell lines, as well as reflecting on recent advances in the generation of human derived beta-cell lines, their use in research studies, and their potential for cell-therapy of diabetes.",
keywords = "Antidiabetic cell-therapy, Beta-cell replacement, Diabetes, Insulin, secreting cell-lines, Pancreatic beta-cell, Pseudoislets",
author = "AD Green and Srividya Vasu and Peter Flatt",
year = "2017",
month = "12",
day = "11",
doi = "10.1111/apha.13012",
language = "English",
volume = "222",
pages = "e13012--e13012",
journal = "Acta Psychologica",
issn = "0001-6918",
publisher = "Elsevier",
number = "3",

}

Cellular models for beta cell function and diabetes gene therapy. / Green, AD; Vasu, Srividya; Flatt, Peter.

In: Acta Psychologica, Vol. 222, No. 3, 11.12.2017, p. e13012-e13012.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cellular models for beta cell function and diabetes gene therapy

AU - Green, AD

AU - Vasu, Srividya

AU - Flatt, Peter

PY - 2017/12/11

Y1 - 2017/12/11

N2 - Diabetes is characterised by the destruction and/or relative dysfunction of insulin secreting beta-cells in the pancreatic islets of Langerhans. Consequently, considerable effort has been made to understand the physiological processes governing insulin production and secretion in these cells, and to elucidate the mechanisms involved in their deterioration in the pathogenesis of diabetes. To date, considerable research has exploited clonal beta-cell lines derived from rodent insulinomas. Such cell-lines have proven to be a great asset in diabetes research, in vitro drug testing, and studies of beta-cell physiology; and provide a sustainable, and in many cases, more practical alternative to the use of animals or primary tissue. However, selection of the most appropriate rodent beta cell-line is often challenging and no single cell line entirely recapitulates the properties of human beta-cells. The generation of stable human beta-cell lines would provide a much more suitable model for studies of human beta-cell physiology and pathology, and could potentially be used as a readily available source of implantable insulin-releasing tissue for cell-based therapies of diabetes. In this review, we discuss the history, development, functional characteristics and use of available clonal rodent beta-cell lines, as well as reflecting on recent advances in the generation of human derived beta-cell lines, their use in research studies, and their potential for cell-therapy of diabetes.

AB - Diabetes is characterised by the destruction and/or relative dysfunction of insulin secreting beta-cells in the pancreatic islets of Langerhans. Consequently, considerable effort has been made to understand the physiological processes governing insulin production and secretion in these cells, and to elucidate the mechanisms involved in their deterioration in the pathogenesis of diabetes. To date, considerable research has exploited clonal beta-cell lines derived from rodent insulinomas. Such cell-lines have proven to be a great asset in diabetes research, in vitro drug testing, and studies of beta-cell physiology; and provide a sustainable, and in many cases, more practical alternative to the use of animals or primary tissue. However, selection of the most appropriate rodent beta cell-line is often challenging and no single cell line entirely recapitulates the properties of human beta-cells. The generation of stable human beta-cell lines would provide a much more suitable model for studies of human beta-cell physiology and pathology, and could potentially be used as a readily available source of implantable insulin-releasing tissue for cell-based therapies of diabetes. In this review, we discuss the history, development, functional characteristics and use of available clonal rodent beta-cell lines, as well as reflecting on recent advances in the generation of human derived beta-cell lines, their use in research studies, and their potential for cell-therapy of diabetes.

KW - Antidiabetic cell-therapy

KW - Beta-cell replacement

KW - Diabetes

KW - Insulin

KW - secreting cell-lines

KW - Pancreatic beta-cell

KW - Pseudoislets

U2 - 10.1111/apha.13012

DO - 10.1111/apha.13012

M3 - Article

VL - 222

SP - e13012-e13012

JO - Acta Psychologica

T2 - Acta Psychologica

JF - Acta Psychologica

SN - 0001-6918

IS - 3

ER -